(Q35112336)

English

Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes

scientific article published on January 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes (English)

1 reference

Europe PubMed Central

6 August 2017

Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes (English)

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

1 reference

based on heuristic

inferred from title

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

author name string

A. B. Gottlieb

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12708779

26 December 2023

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12708779

26 December 2023

publication date

1 January 2003

1 reference

Europe PubMed Central

6 August 2017

full work available at URL

http://journals.sagepub.com/doi/pdf/10.1191/0961203303lu354xx

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

1 reference

Europe PubMed Central

6 August 2017

12

1 reference

Europe PubMed Central

6 August 2017

190-194

1 reference

Europe PubMed Central

6 August 2017

3

1 reference

Europe PubMed Central

6 August 2017

Use of cyclosporin in psoriasis

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Psoriasis. Immunopathology and immunomodulation

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Review article: safety of infliximab in clinical trials

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU354XX

21 January 2018

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

5

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Localization of Neutrophil-Activating Peptide-1/Interleukin-8-Immunoreactivity in Normal and Psoriatic Skin

11

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

In situ localization of interferons in psoriatic lesions

12

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor

15

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Actions of TNF and INF-γ on Angiogenesis In Vitro

16

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

The cytokine network in psoriasis

17

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

22

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

26

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

27

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Severe Psoriasis – Oral Therapy with a New Retinoid

28

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis

32

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

35

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Image of the Month. Pyoderma gangrenosum caused by ulcerative colitis

37

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection

38

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Treatment of longstanding active giant cell arteritis with infliximab: report of four cases

41

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Pyrimidine dimer induction and repair in cultured human skin keratinocytes or melanocytes after irradiation with monochromatic ultraviolet radiation

43

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

44

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study

45

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Archives of Dermatology

46

137

930

author name string

Tan JH

publication date

2001

1 reference

10.1191/0961203303LU354XX

https://api.crossref.org/works/10.1191/0961203303LU354XX

26 December 2023

Identifiers

10.1191/0961203303LU354XX

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35112336&oldid=2040096795"